

Date of Report June 19, 2026

To: CTFD

From: AxisPharm, LLC

Certificate ID Number: 19Jun2026-03



Results reported by: Lab Technician
Ning Yang


Review/Approved by: 
QA Director
Dawei Yue

Sample Received: Date: 06/17/2026
Receiving Condition: ☒ Acceptable ☐ Other: _____
Storage Condition: ☐ Room temperature ☒ -20°C ☐ -80°C
☐ Other: _____

Sample Name: TRIZEPATIDE, 30MG; Batch: TRIZ-30-161-26, BBD: NA

Method(s): LCMS

Procedure(s):
Results:



AxisPharm, LLC

Results only apply to tested Research Use Only samples within Test Report as received. Not for use in humans or animals. Analytical data apply only to the batch tested and do not indicate suitability for diagnostic or therapeutic use. Any unauthorized alteration, reproduction, or relabeling of this COA renders it invalid.



Test Report/ Certificate of Analysis

Sample Name	Amount Measured (mg)	MW (g/mol)	Detected	UV Purity (%)
TRIZEPATIDE, 30MG	29.1	4813.5	2409.0 [M+2H], 1605.9 [M+3H]	99.4%

Salts and sugars that serves as fillers in injectables are not considered as impurities.

Conclusion: The product comes with TRIZEPATIDE, 29.1MG with purity 99.4%.

AxisPharm, LLC

Results only apply to tested Research Use Only samples within Test Report as received. Not for use in humans or animals. Analytical data apply only to the batch tested and do not indicate suitability for diagnostic or therapeutic use. Any unauthorized alteration, reproduction, or relabeling of this COA renders it invalid.